Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIO (teriflunomide)

04-Jun-2012 - Genzyme, a Sanofi company, announced top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS). In the study, ...

Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML

22-Oct-2010 - Genzyme Corporation announced results from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML). Although the study did not show a difference ...

Genzyme Receives FDA Approval for Lumizyme for Pompe Disease

26-May-2010 - Genzyme Corporation announced that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat ...

PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren

05-Mar-2010 - PTC Therapeutics, Inc. and Genzyme Corporation announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). The primary endpoint of change in 6-minute walk distance did not ...

Two-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Continued Improvement Across All Endpoints

16-Feb-2010 - Genzyme Corporation announced two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone ...

Genzyme’s Mozobil Shows Promise in Chemosensitization

10-Dec-2009 - Genzyme Corporation announced that a Phase 1/2 trial provided early clinical data suggesting that Mozobil® (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow. The investigational trial, partially supported by Genzyme, ...

Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL

09-Dec-2009 - Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the ...

Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia

Significant Improvement in Progression Free Survival Seen in Relapsed or Refractory Patients

28-Sep-2009 - Genzyme Corporation announced that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant ...

Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data

Company’s CARE-MS II Phase 3 Trial Completes Enrollment

15-Sep-2009 - Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the ...

Genzyme and Isis Begin New Clinical Trials of Mipomersen

14-Jan-2009 - Genzyme Corp. and Isis Pharmaceuticals, Inc. announced that they have begun two new studies of mipomersen, a novel lipid-lowering drug in late-stage development, and a third is currently screening patients. These three trials will provide additional data on mipomersen in high-risk patient ...